Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

Lookup NU author(s): Professor Matthew CollinORCiD, Professor Andrew GenneryORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2022, The Author(s), under exclusive licence to Springer Nature Limited. Hemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) is a rare syndrome of potentially fatal, uncontrolled hyperinflammation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated in primary, recurrent or progressive HLH, but information about its outcomes in the adult population is limited. We obtained data about 87 adult (≥18 years of age) patients retrospectively reported to the EBMT. The median survival time was 13.9 months. The three and five-year overall survival (OS) was 44% (95% CI 33–54%). Among 39 patients with a follow-up longer than 15 months, only three died. Relapse rate was 21% (95% CI 13–30%), while NRM reached 36% (95% CI 25–46%). Younger patients (<30 years of age) had better prognosis, with an OS of 59% (95% CI 45–73%) at three and five years vs 23% (95% CI 8–37%) for older ones. No difference in survival between reduced and myeloablative conditioning was found. To our knowledge, this is the largest report of adult HLH patients who underwent allo-HSCT. Patients who survive the first period after this procedure can expect a long disease-free survival. Both reduced intensity and myeloablative conditioning have therapeutic potential in adult HLH.


Publication metadata

Author(s): Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema D-J, de Wreede LC, Blok H-J, Isaksson C, Einsele H, Poire X, van Dorp S, Nikolousis E, Johansson J-E, Kobbe G, Zecca M, Arnold R, Gerbitz A, Finke J, Diez-Martin JL, Bonifazi F, McQuaker G, Lenhoff S, Rohrlich P-S, Theobald M, Ljungman P, Collin M, Albert MH, Ehninger G, Carlson K, Halaburda K, Lehmberg K, Schonland S, Yakoub-Agha I, Gennery AR, Lankester AC, Kroger N

Publication type: Article

Publication status: Published

Journal: Bone Marrow Transplantation

Year: 2022

Volume: 57

Pages: 817-823

Online publication date: 24/03/2022

Acceptance date: 02/03/2022

ISSN (print): 0268-3369

ISSN (electronic): 1476-5365

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41409-022-01634-5

DOI: 10.1038/s41409-022-01634-5

PubMed id: 35332305


Altmetrics

Altmetrics provided by Altmetric


Share